Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxi…
35 employees fennecpharma.com
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
News 2026-05-21
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
News release - English.pdf
Results 2026-05-14
Interim MD&A - English.pdf
Results 2026-05-14
Interim financial statements/report – English.pdf
Results 2026-05-14
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
News release - English.pdf
Ownership 2026-05-11
Rallis, Chris Anigeron sold +$24k
Insider trading – 2026-05-11
1 insider · −$24k net
Results 2026-05-07
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
News release - English.pdf
Ownership 2026-05-05
6 insiders · −$32k net
Insider trading – 2026-05-05
6 insiders · −$32k net
News 2026-04-21
Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting
News release - English.pdf
News 2026-04-07
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
News release - English.pdf
Ownership 2026-04-02
Cioffi, Christiana bought +$20k
Insider trading – 2026-04-02
1 insider · +$20k net
Ownership 2026-04-01
Raykov, Rostislav Christov sold +$31k
Insider trading – 2026-04-01
1 insider · −$31k net
Results 2026-03-27
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
News release - English.pdf
Results 2026-03-27 Financials
Annual report on form 10-K - English.pdf
Results 2026-03-27 Financials
Annual MD&A - English.pdf
News 2026-03-27
Auditor's consent letter.pdf
Results 2026-03-27 Financials
Audited annual financial statements – English.pdf
Results 2026-03-24
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
News release - English.pdf
Transactions 2026-03-16 M&A
Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation
News release - English.pdf
Ownership 2026-03-03
2 insiders · −$46k net
Insider trading – 2026-03-03
2 insiders · −$46k net
Ownership 2026-02-24
2 insiders · +$10k net
Insider trading – 2026-02-24
2 insiders · +$10k net
News 2026-02-20
Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
News release - English.pdf
Ownership 2026-02-02
2 insiders · −$42k net
Insider trading – 2026-02-02
2 insiders · −$42k net
Ownership 2026-01-16
Andrade, Robert Christopher bought +$25k
Insider trading – 2026-01-16
1 insider · +$25k net
Ownership 2026-01-08
Andrade, Robert Christopher bought +$35k
Insider trading – 2026-01-08
1 insider · +$35k net
Ownership 2026-01-05
2 insiders · −$40k net
Insider trading – 2026-01-05
2 insiders · −$40k net
Ownership 2025-12-26
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
News release - English.pdf
News 2025-12-26
Early warning report.pdf
Ownership 2025-12-24
Southpoint Capital Advisors LP sold +$7.7M
Insider trading – 2025-12-24
1 insider · −$7.7M net
News 2025-12-11
Report of exempt distribution (45-106F1) (amended).pdf
News 2025-12-09
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
News release - English.pdf
Ownership 2025-12-05
Raykov, Rostislav Christov sold +$75k
Insider trading – 2025-12-05
1 insider · −$75k net
Ownership 2025-12-03
2 insiders · $0 net
Insider trading – 2025-12-03
2 insiders · $0 net
Results 2025-12-02
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
News release - English.pdf
Transactions 2025-11-19 Financing
Fennec Pharmaceuticals Inc. announced it has repurchased and redeemed all of its outstanding convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP using proceeds from the closing of the Company's previously announced underwritten public offering in the United States and concurrent private placement in Canada, closed on November 17 and 18, 2025, respectively. The Company has no outstanding debt after the redemption of Petrichor's convertible notes.
Material change report - English.pdf
Transactions 2025-11-19 Financing
Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
News release - English.pdf
News 2025-11-18
Report of exempt distribution (45-106F1).pdf
Transactions 2025-11-18 Financing
Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada
News release - English.pdf
Transactions 2025-11-18 Financing
Fennec Pharmaceuticals Inc. Announces Closing of Previously Announced Underwritten Registered Public Offering
Material change report - English.pdf
Ownership 2025-11-18
Southpoint Capital Advisors LP sold +$2.0M
Insider trading – 2025-11-18
1 insider · −$2.0M net
Transactions 2025-11-17 Financing
Fennec Pharmaceuticals Announces Closing of Offering of Common Shares
News release - English.pdf
News 2025-11-14
Offering document - English.pdf
News 2025-11-14
News release - English.pdf
News 2025-11-14
News release - English.pdf
News 2025-11-13
News release - English.pdf
Results 2025-11-13 Financials
Interim MD&A - English.pdf
Results 2025-11-13 Financials
Interim financial statements/report – English.pdf
News 2025-11-13
News release - English.pdf
Ownership 2025-11-06
2 insiders · −$81k net
Insider trading – 2025-11-06
2 insiders · −$81k net
Ownership 2025-10-10
3 insiders · −$636k net
Insider trading – 2025-10-10
3 insiders · −$636k net
Ownership 2025-10-02
2 insiders · $0 net
Insider trading – 2025-10-02
2 insiders · $0 net
Ownership 2025-09-16
Raykov, Rostislav Christov bought +$89k
Insider trading – 2025-09-16
1 insider · +$89k net
Ownership 2025-09-05
Raykov, Rostislav Christov sold +$89k
Insider trading – 2025-09-05
1 insider · −$89k net
Ownership 2025-09-04
2 insiders · $0 net
Insider trading – 2025-09-04
2 insiders · $0 net
Results 2025-08-15 Financials
Interim financial statements/report – English.pdf
Results 2025-08-15 Financials
Interim MD&A - English.pdf
News 2025-08-15
News release - English.pdf
News 2025-08-14
News release - English.pdf
News 2025-08-11
News release - English.pdf
Ownership 2025-08-05
Raykov, Rostislav Christov sold +$81k
Insider trading – 2025-08-05
1 insider · −$81k net
Ownership 2025-08-04
2 insiders · $0 net
Insider trading – 2025-08-04
2 insiders · $0 net
Ownership 2025-07-08
Rallis, Chris Anigeron sold +$5k
Insider trading – 2025-07-08
1 insider · −$5k net
Ownership 2025-07-04
Raykov, Rostislav Christov sold +$86k
Insider trading – 2025-07-04
1 insider · −$86k net
Ownership 2025-07-02
2 insiders · $0 net
Insider trading – 2025-07-02
2 insiders · $0 net
Ownership 2025-06-09
Raykov, Rostislav Christov sold +$78k
Insider trading – 2025-06-09
1 insider · −$78k net
Ownership 2025-06-04
2 insiders · +$42k net
Insider trading – 2025-06-04
2 insiders · +$42k net
Ownership 2025-05-19
3 insiders · −$8k net
Insider trading – 2025-05-19
3 insiders · −$8k net
Ownership 2025-05-01
2 insiders · $0 net
Insider trading – 2025-05-01
2 insiders · $0 net
Ownership 2025-04-11
Rallis, Chris Anigeron sold +$2k
Insider trading – 2025-04-11
1 insider · −$2k net
Ownership 2025-04-08
Raykov, Rostislav Christov sold +$53k
Insider trading – 2025-04-08
1 insider · −$53k net
Ownership 2025-04-03
2 insiders · $0 net
Insider trading – 2025-04-03
2 insiders · $0 net
Ownership 2025-03-06
Raykov, Rostislav Christov sold +$68k
Insider trading – 2025-03-06
1 insider · −$68k net
Ownership 2025-03-04
2 insiders · $0 net
Insider trading – 2025-03-04
2 insiders · $0 net
Ownership 2025-02-14
Rallis, Chris Anigeron bought +$492k
Insider trading – 2025-02-14
1 insider · +$492k net
Ownership 2025-02-05
2 insiders · −$67k net
Insider trading – 2025-02-05
2 insiders · −$67k net
Ownership 2025-01-08
Raykov, Rostislav Christov sold +$61k
Insider trading – 2025-01-08
1 insider · −$61k net
Ownership 2025-01-06
2 insiders · $0 net
Insider trading – 2025-01-06
2 insiders · $0 net
Ownership 2024-12-23
Raykov, Rostislav Christov bought +$67k
Insider trading – 2024-12-23
1 insider · +$67k net
Ownership 2024-12-05
2 insiders · +$15k net
Insider trading – 2024-12-05
2 insiders · +$15k net
Ownership 2024-11-21
Andrade, Robert Christopher bought +$39k
Insider trading – 2024-11-21
1 insider · +$39k net
Ownership 2024-10-08
Rallis, Chris Anigeron sold +$1k
Insider trading – 2024-10-08
1 insider · −$1k net
Ownership 2024-10-04
2 insiders · −$12k net
Insider trading – 2024-10-04
2 insiders · −$12k net
Ownership 2024-09-06
Raykov, Rostislav Christov sold +$13k
Insider trading – 2024-09-06
1 insider · −$13k net
Ownership 2024-09-03
2 insiders · $0 net
Insider trading – 2024-09-03
2 insiders · $0 net
Ownership 2024-08-02
2 insiders · −$15k net
Insider trading – 2024-08-02
2 insiders · −$15k net
Ownership 2024-07-08
Rallis, Chris Anigeron sold +$2k
Insider trading – 2024-07-08
1 insider · −$2k net
Ownership 2024-07-03
2 insiders · −$15k net
Insider trading – 2024-07-03
2 insiders · −$15k net